These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22305721)

  • 41. IGF-I abuse in sport: current knowledge and future prospects for detection.
    Guha N; Sönksen PH; Holt RI
    Growth Horm IGF Res; 2009 Aug; 19(4):408-11. PubMed ID: 19467615
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Application of the Athlete Biological Passport Approach to the Detection of Growth Hormone Doping.
    Equey T; Pastor A; de la Torre Fornell R; Thomas A; Giraud S; Thevis M; Kuuranne T; Baume N; Barroso O; Aikin R
    J Clin Endocrinol Metab; 2022 Feb; 107(3):649-659. PubMed ID: 34726230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of immunoassays for the measurement of insulin-like growth factor-I and procollagen type III peptide, indirect biomarkers of recombinant human growth hormone misuse in sport.
    Abellan R; Ventura R; Pichini S; Pascual JA; Pacifici R; Di Carlo S; Bacosi A; Segura J; Zuccaro P
    Clin Chem Lab Med; 2005; 43(1):75-85. PubMed ID: 15653447
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Overview of the legal framework applicable to the marker method for the detection of human growth hormone.
    Young RR; Bielak JS; Horvitz SL
    Growth Horm IGF Res; 2009 Aug; 19(4):366-8. PubMed ID: 19608446
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Laboratory issues in the implementation of the marker method.
    Cowan DA; Bartlett C
    Growth Horm IGF Res; 2009 Aug; 19(4):357-60. PubMed ID: 19574074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Growth hormone doping in sports: a critical review of use and detection strategies.
    Baumann GP
    Endocr Rev; 2012 Apr; 33(2):155-86. PubMed ID: 22368183
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effectiveness of GH isoform differential immunoassay for detecting rhGH doping on application of various growth factors.
    Okano M; Nishitani Y; Sato M; Kageyama S
    Drug Test Anal; 2012 Sep; 4(9):692-700. PubMed ID: 22733714
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The GH-2004 project: the response of IGF1 and type III pro-collagen to the administration of exogenous GH in non-Caucasian amateur athletes.
    Holt RI; Erotokritou-Mulligan I; McHugh C; Bassett EE; Bartlett C; Fityan A; Bacon JL; Cowan DA; Sönksen PH
    Eur J Endocrinol; 2010 Jul; 163(1):45-54. PubMed ID: 20421332
    [TBL] [Abstract][Full Text] [Related]  

  • 49. 20K-GH and its use in detecting GH abuse.
    Irie M; Ueki M; Kishikawa Y; Nishii M; Kawahara T
    Growth Horm IGF Res; 2009 Aug; 19(4):352-6. PubMed ID: 19487145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of normal distribution-based and nonparametric decision limits on the GH-2000 score for detecting growth hormone misuse (doping) in sport.
    Liu W; Bretz F; Böhning D; Holt R; Böhning W; Guha N; Sönksen P; Cowan D
    Biom J; 2021 Jan; 63(1):187-200. PubMed ID: 33164238
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Serum IGF-I measured by four different immunoassays in patients with adult GH deficiency or acromegaly and in a control population.
    Granada ML; Ulied A; Casanueva FF; Pico A; Lucas T; Torres E; Sanmartí A
    Clin Endocrinol (Oxf); 2008 Jun; 68(6):942-50. PubMed ID: 17980002
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mass spectrometric characterization of a biotechnologically produced full-length mechano growth factor (MGF) relevant for doping controls.
    Thevis M; Thomas A; Geyer H; Schänzer W
    Growth Horm IGF Res; 2014 Dec; 24(6):276-80. PubMed ID: 25466910
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Erythropoietin administration does not influence the GH--IGF axis or makers of bone turnover in recreational athletes.
    Nelson AE; Howe CJ; Nguyen TV; Seibel MJ; Baxter RC; Handelsman DJ; Kazlauskas R; Ho KK
    Clin Endocrinol (Oxf); 2005 Sep; 63(3):305-9. PubMed ID: 16117818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A robust test for growth hormone doping--present status and future prospects.
    Nelson AE; Ho KK
    Asian J Androl; 2008 May; 10(3):416-25. PubMed ID: 18385903
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Quantification of human insulin-like growth factor-1 and qualitative detection of its analogues in plasma using liquid chromatography/electrospray ionisation tandem mass spectrometry.
    Bredehöft M; Schänzer W; Thevis M
    Rapid Commun Mass Spectrom; 2008; 22(4):477-85. PubMed ID: 18236437
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New detection methods of growth hormone and growth factors.
    Bidlingmaier M
    Endocr Dev; 2012; 23():52-9. PubMed ID: 23182820
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Detecting growth hormone abuse in athletes.
    Bidlingmaier M; Manolopoulou J
    Endocrinol Metab Clin North Am; 2010 Mar; 39(1):25-32, vii. PubMed ID: 20122447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The association between insulin-like growth factor I and bone turnover markers in the general adult population.
    Niemann I; Hannemann A; Nauck M; Spielhagen C; Völzke H; Wallaschofski H; Friedrich N
    Bone; 2013 Sep; 56(1):184-90. PubMed ID: 23792936
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Growth hormone and the adolescent athlete: What are the data for its safety and efficacy as an ergogenic agent?
    Rogol AD
    Growth Horm IGF Res; 2009 Aug; 19(4):294-9. PubMed ID: 19487146
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The intra-individual stability of GH biomarkers IGF-I and P-III-NP in relation to GHRH administration, menstrual cycle, and hematological parameters.
    Ericsson M; Bhuiyan H; Yousif B; Lehtihet M; Ekström L
    Drug Test Anal; 2020 Nov; 12(11-12):1620-1628. PubMed ID: 33125822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.